101 related articles for article (PubMed ID: 23832427)
1. Commentary.
Mahler RJ
Diabetes Metab Res Rev; 2013 Jul; 29(5):427-8. PubMed ID: 23832427
[No Abstract] [Full Text] [Related]
2. Saxagliptin, alogliptin, and cardiovascular outcomes.
Scirica BM; Braunwald E; Bhatt DL
N Engl J Med; 2014 Jan; 370(5):483-4. PubMed ID: 24476444
[No Abstract] [Full Text] [Related]
3. No heart risk--or benefit--from diabetes drug Onglyza.
Harv Heart Lett; 2013 Dec; 24(4):8. PubMed ID: 27024811
[No Abstract] [Full Text] [Related]
4. Saxagliptin efficacy.
Valiquette G
Diabetes Obes Metab; 2010 Aug; 12(8):734; author reply 735. PubMed ID: 20590752
[No Abstract] [Full Text] [Related]
5. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
Borja-Hart NL; Whalen KL
Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
[TBL] [Abstract][Full Text] [Related]
6. No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations.
Jialal I; Dhindsa S
Metab Syndr Relat Disord; 2014 Apr; 12(3):157-8. PubMed ID: 24520851
[No Abstract] [Full Text] [Related]
7. ACP Journal Club. In at-risk patients with type 2 diabetes, saxagliptin and placebo did not differ for CV events.
Morey-Vargas OL; Montori VM
Ann Intern Med; 2014 Jan; 160(2):JC8-9. PubMed ID: 24445719
[No Abstract] [Full Text] [Related]
8. Saxagliptin, alogliptin, and cardiovascular outcomes.
Standl E
N Engl J Med; 2014 Jan; 370(5):483. PubMed ID: 24476445
[No Abstract] [Full Text] [Related]
9. In AF or VTE, warfarin dosing by genotype improved time in therapeutic range but not clinical outcomes.
Dunn A
Ann Intern Med; 2014 Mar; 160(6):JC9. PubMed ID: 24638187
[No Abstract] [Full Text] [Related]
10. Lessons from SAVOR and EXAMINE: some important answers, but many open questions.
Schernthaner G; Sattar N
J Diabetes Complications; 2014; 28(4):430-3. PubMed ID: 24713467
[No Abstract] [Full Text] [Related]
11. Saxagliptin and Heart Failure in the SAVOR-TIMI 53 Trial: Reflections on the Bradford Hill Criteria.
Cebrián Cuenca AM; Orozco Beltrán D; Navarro Pérez J; Álvarez-Guisasola F; Núñez Villota J; Consuegra-Sánchez L
Rev Esp Cardiol (Engl Ed); 2017 Dec; 70(12):1143-1144. PubMed ID: 28284632
[No Abstract] [Full Text] [Related]
12. Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial.
Hardy G
Cardiovasc J Afr; 2013 Aug; 24(7):290. PubMed ID: 24217308
[No Abstract] [Full Text] [Related]
13. FDA approves saxagliptin for type 2 diabetes.
Traynor K
Am J Health Syst Pharm; 2009 Sep; 66(17):1513. PubMed ID: 19710429
[No Abstract] [Full Text] [Related]
14. Saxagliptin and tuberculosis.
Prescrire Int; 2013 Jan; 22(134):17. PubMed ID: 23383408
[No Abstract] [Full Text] [Related]
15. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
Schernthaner G; Cahn A; Raz I
Diabetes Care; 2016 Aug; 39 Suppl 2():S210-8. PubMed ID: 27440835
[No Abstract] [Full Text] [Related]
16. [Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
MMW Fortschr Med; 2014 Jul; 156(13):74-5. PubMed ID: 25318234
[No Abstract] [Full Text] [Related]
17. Diabetes: Cardiovascular safety of 'gliptin' therapy.
Lim GB
Nat Rev Cardiol; 2013 Nov; 10(11):616. PubMed ID: 24042219
[No Abstract] [Full Text] [Related]
18. Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
Greenhill C
Nat Rev Endocrinol; 2013 Nov; 9(11):625. PubMed ID: 24061081
[No Abstract] [Full Text] [Related]
19. Place in therapy for liraglutide and saxagliptin for type 2 diabetes and FDA liraglutide warning.
McFarland MS; Brock M; Ryals C
South Med J; 2011 Aug; 104(8):612. PubMed ID: 21886074
[No Abstract] [Full Text] [Related]
20. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
Simó R; Hernández C
Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
[No Abstract] [Full Text] [Related]
[Next] [New Search]
